

DAFTAR PUSTAKA

1. Huang R, Mo D, Wu J, Ai H, Lu Y. CD133 expression correlates with clinicopathologic features and poor prognosis of colorectal cancer patients: An updated meta-analysis of 37 studies. *Medicine*. 2018: 1-9.
2. Latifah R. Karakteristik Klinis Penderita Kanker Kolorektal Di Indonesia – Suatu Studi Literatur. 2020.
3. Xi Y, Xu P. Global colorectal cancer burden in 2020 and projections to 2040. *Transl Oncol*. 2021.
4. Baran B, Mert ON, Yerli Tetik N, Acar E, Bekcioglu O, Baskin Y. Difference Between Left-Sided and Right-Sided Colorectal Cancer: A Focused Review of Literature. *Gastroenterology Res*. 2018
5. Huang JL, Oshi M, Endo I, Takabe K. Clinical relevance of stem cell surface markers CD133, CD24, and CD44 in colorectal cancer. *Am J Cancer Res*. 2021: 5141-4.
6. Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM, Jemal A, Kramer JL, Siegel RL. Cancer treatment and survivorship statistics, 2019. *CA Cancer J Clin*. 2019 :363-85.
7. Kim HJ, Choi GS. Clinical Implications of Lymph Node Metastasis in Colorectal Cancer: Current Status and Future Perspectives. *Ann Coloproctol*. 2019: 109-17.
8. Ong ML, Schofield JB. Assessment of lymph node involvement in colorectal cancer. *World J Gastrointest Surg*. 2016: 179-92.
9. Ren F, Sheng WQ, Du X. CD133: A cancer stem cells marker, is used in colorectal cancers. *World J Gastroenterol*. 2013: 2603-11.
10. Zhou Y, Xia L, Wang H, Oyang L, Su M, et al. Cancer stem cells in progression of colorectal cancer. *Oncotarget*. 20187: 33403-15.
11. Moharil R, Dive A, Khandekar S, Bodhade A. Cancer stem cells: An insight. *J Oral Maxillofac Pathol*. 2017.
12. Kabakov A, Yakimova A, Matchuk O. Molecular Chaperones in Cancer Stem Cells: Determinants of Stemness and Potential Targets for Antitumor Therapy. *Cells*. 2020.
13. Glumac PM, LeBeau AM. The role of CD133 in cancer: a concise review. *Clin Transl Med*. 2018.
14. Krause M, Dubrovskaya A, Linge A, Baumann M. Cancer stem cells: Radioresistance, prediction of radiotherapy outcome and specific targets for combined treatments. *Adv Drug Deliv Rev*. 2017: 63-73.
15. Kim WT, Ryu CJ. Cancer stem cell surface markers on normal stem cells. *BMB Rep*. 2017: 285-98.
16. Rezaee M, Gheytaichi E, Madjd Z, Mehrazma M. Clinicopathological significance of

- tumor stem cell markers ALDH1 and CD133 in colorectal carcinoma. *Iran J Pathol.* 2021: 40-50.
17. Hervieu C, Christou N, Battu S, Mathonnet M. The role of cancer stem cells in colorectal cancer: From the basics to novel clinical trials. *Cancers.* 2021.
 18. Safa AR. Drug and apoptosis resistance in cancer stem cells: a puzzle with many pieces. *Cancer Drug Resist.* 2022: 850-72.
 19. Li R, Dong H, Zhu J, Yi H, Liu S. Overexpression of CD133 confers poor prognosis in colorectal cancer: a systematic review and meta-analysis. *Int J Clin Exp Med.* 2019: 1492-502.
 20. Phi LTH, Sari IN, Yang YG, Lee SH, Jun N, Kim KS, Lee YK, Kwon HY. Cancer Stem Cells (CSCs) in Drug Resistance and their Therapeutic Implications in Cancer Treatment. *Stem Cells Int.* 2018
 21. De Sousa e Melo F, Kurtova AV, Harnoss JM, Kljavin N, Hoeck JD, et al. A distinct role for Lgr5⁺ stem cells in primary and metastatic colon cancer. *Nature.* 2017.
 22. Michl M, Taverna F, Kumbrink J, Schiergens TS, Heinemann V, et al. Biomarker alterations associated with distinct patterns of metastatic spread in colorectal cancer. *Virchows Arch.* 2021: 695-705.
 23. Haussmann J, Matuschek C, Bölke E, Orth K, Ghadjar P, Budach W. The Role of Local Treatment in Oligometastatic and Oligoprogressive Cancer. *Dtsch Arztebl Int.* 2019: 849-56.
 24. Stintzing S, Miller-Phillips L, Modest DP, Fischer von Weikersthal L, Decker T, et al. Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study. *Eur J Cancer.* 2017: 50-60.
 25. Pop MG. *Basic Principles and Practice in Surgery.* Chapter 2, Stem Cell Markers in Colon Cancer. IntechOpen 2019.
 26. Barzegar Behrooz A, Syahir A, Ahmad S. CD133: beyond a cancer stem cell biomarker. *J Drug Target.* 2019: 257-69.
 27. Kholodenko IV, Kim YS, Gisina AM, Lupatov AY, Kholodenko RV, Yarygin KN. Analysis of the Correlation between CD133 Expression on Human Colorectal Adenocarcinoma Cells HT-29 and Their Resistance to Chemotherapeutic Drugs. *Bull Exp Biol Med.* 2021: 156-63.
 28. Devrim T, Karahan N, Baspinar S, Bozkurt KK, Kocer M, Kapucuoglu N. Clinicopathologic significance of high CD133 expression in colorectal carcinomas. *Med J SDU.* 2015: 32-8.
 29. Hong I, Hong SW, Chang YG, Lee WY, Lee B, et al. Expression of the Cancer Stem Cell Markers CD44 and CD133 in Colorectal Cancer: An Immunohistochemical Staining Analysis. *Ann Coloproctol.* 2015: 84-91.

30. Rey I, Putra A, Lindarto D, Yusuf F. Association between CD133 expression and clinicopathological profile in colorectal cancer. *Med Glas.* 2020: 402-407.
31. Chen S, Song X, Chen Z, Li X, Li M, Liu H, Li J. CD133 expression and the prognosis of colorectal cancer: a systematic review and meta-analysis. *PLoS One.* 2013
32. Mia-Jan, K., Jung, S.Y., Kim, IY. *et al.* CD133 expression is not an independent prognostic factor in stage II and III colorectal cancer but may predict the better outcome in patients with adjuvant therapy. *BMC Cancer.* 2013
33. Kazama S, Kishikawa J, Kiyomatsu T, Kawai K, Nozawa H, et al. Expression of the stem cell marker CD133 is related to tumor development in colorectal carcinogenesis. *Asian J Surg.* 2018: 274-8.
34. Greenson JK. Diagnostic pathology gastrointestinal. Chapter 5, Colon. Elsevier 2016: 480-9.
35. WHO Classification of Tumours Editorial Board. WHO classification of tumours, Digestive System Tumours. Chapter 6, Tumours of the colon and rectum. World Health Organization 2019: 177-87.
36. Mármol I, Sánchez-de-Diego C, Dieste AP, Cerrada E, Yoldi MJ. Colorectal carcinoma: A general overview and future perspectives in colorectal cancer. *Int J Mol Sci.* 2017.
37. Das P, Majumdar K, Gupta SD. *Surgical Pathology of the Gastrointestinal System.* Chapter 3, Neoplastic Disease. Springer 2022: 756-66.
38. Müller MF, Ibrahim AE, Arends MJ. Molecular pathological classification of colorectal cancer. *Virchows Arch.* 2016: 125-34.
39. Goldblum JR, Lamps LW, McKenney JK, Myers JL. *Rosai and Ackerman's Surgical Pathology.* Chapter 17, Large Bowel. Elsevier 2018: 668-88.
40. Tateishi Y, Nakanishi Y, Taniguchi H, Shimoda T, Umemura S. Pathological prognostic factors predicting lymph node metastasis in submucosal invasive (T1) colorectal carcinoma. *Mod Pathol.* 2010: 1068-72.
41. Phipps AI, Lindor NM, Jenkins MA, Baron JA, Win AK, et al. Colon and rectal cancer survival by tumor location and microsatellite instability: the Colon Cancer Family Registry. *Dis Colon Rectum.* 2013: 937-44.
42. Nakagawa-Senda H, Hori M, Matsuda T, Ito H. Prognostic impact of tumor location in colon cancer: the Monitoring of Cancer Incidence in Japan (MCIJ) project. *BMC Cancer.* 2019.
43. Zhang Z, Wang A, Tang X, Chen Y, Tang E, Jiang H. Comparative mutational analysis of distal colon cancer with rectal cancer. *Oncol Lett.* 2020: 1781-8.
44. van der Sijp MP, Bastiaannet E, Mesker WE, van der Geest LG, Breugom AJ, et al. Differences between colon and rectal cancer in complications, short-term survival and recurrences. *Int J Colorectal Dis.* 2016: 1683-91.
45. Karaman S, Detmar M. Mechanisms of lymphatic metastasis. *J Clin Invest.* 2014: 922-8.

46. Resch A, Langner C. Lymph node staging in colorectal cancer: old controversies and recent advances. *World J Gastroenterol*. 2013.
47. Karjol U, Jonnada P, Chandranath A, Cherukuru S. Lymph Node Ratio as a Prognostic Marker in Rectal Cancer Survival: A Systematic Review and Meta-Analysis. *Cureus*. 2020.
48. Yadav AK, Desai NS. Cancer Stem Cells: Acquisition, Characteristics, Therapeutic Implications, Targeting Strategies and Future Prospects. *Stem Cell Rev Rep*. 2019: 331-55.
49. Jiao X, Qian X, Wu L, Li B, Wang Y, Kong X, Xiong L. microRNA: The Impact on Cancer Stemness and Therapeutic Resistance. *Cells*. 2019.
50. Yang L, Shi P, Zhao G, Xu J, Peng W, Zet al. Targeting cancer stem cell pathways for cancer therapy. *Signal Transduct Target Ther*. 2020.
51. Jin X, Jin X, Kim H. Cancer stem cells and differentiation therapy. *Tumour Biol*. 2017.
52. Lathia JD, Liu H. Overview of Cancer Stem Cells and Stemness for Community Oncologists. *Target Oncol*. 2017: 387-99.
53. Prager BC, Xie Q, Bao S, Rich JN. Cancer Stem Cells: The Architects of the Tumor Ecosystem. *Cell Stem Cell*. 2019: 41-53.
54. Cojoc M, Mäbert K, Muders MH, Dubrovska A. A role for cancer stem cells in therapy resistance: cellular and molecular mechanisms. *Semin Cancer Biol*. 2015
55. Spelt L, Sasor A, Ansari D, Hilmersson KS, Andersson R. The Prognostic Role of Cancer Stem Cell Markers for Long-term Outcome After Resection of Colonic Liver Metastases. *Anticancer Res*. 2018: 313-20.
56. Ribeiro KB, da Silva Zanetti J, Ribeiro-Silva A, Rapatoni L, de Oliveira HF, et al. KRAS mutation associated with CD44/CD166 immunoexpression as predictors of worse outcome in metastatic colon cancer. *Cancer Biomark*. 2016: 513-21.
57. Holah NS, Aiad HA, Asaad NY, Elkhoulouy EA, Lasheen AG. Evaluation of the Role of ALDH1 as Cancer Stem Cell Marker in Colorectal Carcinoma: An Immunohistochemical Study. *J Clin Diagn Res*. 2017.
58. Ismaiel NE, Sharaf WM, Helmy DO, Zaki MM, Badawi MA, Soliman AS. Detection of Cancer Stem Cells in Colorectal Cancer: Histopathological and Immunohistochemical Study. *Open Access Maced J Med Sci*. 2016: 543-7.
59. Nosrati A, Naghshvar F, Maleki I, Salehi F. Cancer stem cells CD133 and CD24 in colorectal cancers in Northern Iran. *Gastroenterol Hepatol Bed Bench*. 2016: 132-9.
60. Seeber A, Untergasser G, Spizzo G, Terracciano L, Lugli A, et al. Predominant expression of truncated EpCAM is associated with a more aggressive phenotype and predicts poor overall survival in colorectal cancer. *Int J Cancer*. 2016: 657-63.

61. Gires O, Pan M, Schinke H, Canis M, Baeuerle PA. Expression and function of epithelial cell adhesion molecule EpCAM: where are we after 40 years? *Cancer Metastasis Rev.* 2020: 969-87.
62. Dana H, Marmari V, Mahmoodi G, Mahmoodzadeh H, Ebrahimi M, Mehmandoost N. CD166 as a Stem Cell Marker? A Potential Target for Therapy Colorectal Cancer? *J. Stem Cell Res.* 2016.
63. Hatano Y, Fukuda S, Hisamatsu K, Hirata A, Hara A, Tomita H. Multifaceted Interpretation of Colon Cancer Stem Cells. *Int J Mol Sci.* 2017.
64. Han S, Yang W, Zong S, Li H, Liu S, et al. Clinicopathological, prognostic and predictive value of CD166 expression in colorectal cancer: a meta-analysis. *Oncotarget.* 2017: 64373-84.
65. Hamidi H, Pietilä M, Ivaska J. The complexity of integrins in cancer and new scopes for therapeutic targeting. *Br J Cancer.* 2016.
66. Shekarriz R, Montazer F, Alizadeh-Navaei R. Overexpression of cancer stem cell marker Lgr5 in colorectal cancer patients and association with clinicopathological findings. *Caspian J Intern Med.* 2019: 412-6
67. Zheng Z, Yu H, Huang Q, Wu H, Fu Y, et al.. Heterogeneous expression of Lgr5 as a risk factor for focal invasion and distant metastasis of colorectal carcinoma. *Oncotarget.* 2018: 30025-33.
68. Kozovska Z, Patsalias A, Bajzik V, Durinikova E, Demkova L, et al ALDH1A inhibition sensitizes colon cancer cells to chemotherapy. *BMC Cancer.* 2018.
69. Chen J, Xia Q, Jiang B, Chang W, Yuan W, et al. Prognostic Value of Cancer Stem Cell Marker ALDH1 Expression in Colorectal Cancer: A Systematic Review and Meta-Analysis. *PLoS One.* 2015.
70. Holah NS, Aiad HA, Asaad NY, Elkhoully EA, Lasheen AG. Evaluation of the Role of ALDH1 as Cancer Stem Cell Marker in Colorectal Carcinoma: An Immunohistochemical Study. *J Clin Diagn Res.* 2017
71. Thamm K, Graupner S, Werner C, Huttner WB, Corbeil D. Monoclonal Antibodies 13A4 and AC133 Do Not Recognize the Canine Ortholog of Mouse and Human Stem Cell Antigen Prominin-1 (CD133). *PLoS One.* 2016.
72. Su YJ, Lin WH, Chang YW, Wei KC, Liang CL, et al. Polarized cell migration induces cancer type-specific CD133/integrin/Src/Akt/GSK3 β / β -catenin signaling required for maintenance of cancer stem cell properties. *Oncotarget.* 2015: 38029-45.
73. Maeda K, Ding Q, Yoshimitsu M, Kuwahata T, Miyazaki Y, et al. CD133 Modulate HIF-1 α Expression under Hypoxia in EMT Phenotype Pancreatic Cancer Stem-Like Cells. *Int J Mol Sci.* 2016
74. Gonzalez-Villarreal CA, Quiroz-Reyes AG, Islas JF, Garza-Treviño EN. Colorectal Cancer Stem Cells in the Progression to Liver Metastasis. *Front Oncol.* 2020

75. Li F, Zhou K, Gao L, Zhang B, Li W, et al. Radiation induces the generation of cancer stem cells: A novel mechanism for cancer radioresistance. *Oncol Lett.* 2016: 3059-65.
76. Munakata K, Uemura M, Tanaka S, Kawai K, Kitahara T, et al. Cancer Stem-like Properties in Colorectal Cancer Cells with Low Proteasome Activity. *Clin Cancer Res.* 2016: 5277-86.
77. Barrantes-Freer A, Renovanz M, Eich M, Braukmann A, Sprang B, et al. CD133 Expression Is Not Synonymous to Immunoreactivity for AC133 and Fluctuates throughout the Cell Cycle in Glioma Stem-Like Cells. *PLoS One.* 2015.
78. He S, Zhou H, Zhu X, Hu S, Fei M, et al. Expression of Lgr5, a marker of intestinal stem cells, in colorectal cancer and its clinicopathological significance. *Biomed Pharmacother.* 2014: 507-13.
79. Hongo K, Kazama S, Sunami E, Tsuno NH, Takahashi K, Nagawa H, Kitayama J. Immunohistochemical detection of CD133 is associated with tumor regression grade after chemoradiotherapy in rectal cancer. *Med Oncol.* 2012: 2849-57.
80. Ehteram H, Aslanbeigi F, Ghoochani Khorasani E, Tolouee M, Haddad Kashani H. Expression and Prognostic Significance of Stem Cell Marker CD133 in Survival Rate of Patients with Colon Cancer. *Oncol Ther.* 2022:451-61.
81. Lemeshow S, Hosmer DW, Klar J, Lwanga SK. Adequacy of Sample Size in Health Studies. Chapter 8, Sample size for sample surveys. World Health Organization. 1990:41-7.
82. Dumont F, Muñoz MA, De Franco V, Wernert R, Verrielle V, et al. Significance of lymph node involvement in local recurrence of colorectal cancer. *J Surg Oncol.* 2019: 722-728.
83. Yahya A, Alhamadani Z, Mundher M. Immunohistochemical expression of retinoblastoma gene product and p53 protein in transitional cell carcinoma of the urinary bladder and its relationship to different clinicopathological parameters. *J Med Sci.* 2021
84. Attia S, Atwan N, Arafa M, Shahin RA. Expression of CD133 as a cancer stem cell marker in invasive gastric carcinoma. *Pathologica.* 2019:18-23.
85. Varghese F, Bukhari AB, Malhotra R, De A. IHC Profiler: an open source plugin for the quantitative evaluation and automated scoring of immunohistochemistry images of human tissue samples. *PLoS One.* 2014
86. Dwijayanthi NKA, Dewi ANN, Mahayasa IM, Surudarma IW. Karakteristik Pasien Kanker Kolorektal di Rumah Sakit Umum Pusat Sanglah Berdasarkan Data Demografi, Temuan Klinis, dan Gaya Hidup. *J Med Udayana.* 2020
87. Nasution N. Karakteristik Pasien Kanker Kolorektal di RSUP H. Adam Malik Medan Tahun 2015-2017. 2018
88. American Society. Colorectal Cancer Facts & Figures 2020-2022. [Last cited 2023 February 21]. Available from: <https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/colorectal-cancer-facts-and-figures/colorectal-cancer-facts-and-figures-2020-2022.pdf>

89. Lewandowska A, Rudzki G, Lewandowski T, Strykowska-Góra A, Rudzki S. Title: Risk Factors for the Diagnosis of Colorectal Cancer. *Cancer Control*. 2022
90. Komite Penanggulangan Kanker Nasional. Panduan Penatalaksanaan Kanker Kolorektal. 2016
91. Laconi E, Marongiu F, DeGregori J. Cancer as a disease of old age: changing mutational and microenvironmental landscapes. *Br J Cancer*. 2020
92. Sawicki T, Ruszkowska M, Danielewicz A, Niedźwiedzka E, Arłukowicz T, Przybyłowicz KE. A Review of Colorectal Cancer in Terms of Epidemiology, Risk Factors, Development, Symptoms and Diagnosis. *Cancers (Basel)*. 2021
93. Carethers JM. Risk factors for colon location of cancer. *Transl Gastroenterol Hepatol*. 2018
94. Tadros M, Mago S, Miller D, Ungemack JA, Anderson JC, Swede H. The rise of proximal colorectal cancer: a trend analysis of subsite specific primary colorectal cancer in the SEER database. *Ann Gastroenterol*. 2021
95. Kang S, Na Y, Joung SY, Lee SI, Oh SC, Min BW. The significance of microsatellite instability in colorectal cancer after controlling for clinicopathological factors. *Medicine*. 2018
96. Minhajat R. The relationship between histopathological grading and metastasis in colorectal carcinoma patients. *Nusant Med Sci J*. 2021
97. Park YY, An CH, Oh ST, Chang ED, Lee J. Expression of CD133 is associated with poor prognosis in stage II colorectal carcinoma. *Medicine*. 2019
98. Nomura M, Takahashi H, Fujii M, Miyoshi N, Haraguchi N, et al. Clinical significance of invasion distance relative to prognosis in pathological T3 colorectal cancer. *Oncol Lett*. 2019
99. Fleming M, Ravula S, Tatishchev SF, Wang HL. Colorectal carcinoma: Pathologic aspects. *J Gastrointest Oncol*. 2012:153-73.
100. Lin CC, Liao TT, Yang MH. Immune Adaptation of Colorectal Cancer Stem Cells and Their Interaction With the Tumor Microenvironment. *Front Oncol*. 2020
101. Mare M, Colarossi L, Veschi V, Turdo A, Giuffrida D, et al. Cancer Stem Cell Biomarkers Predictive of Radiotherapy Response in Rectal Cancer: A Systematic Review. *Genes*. 2021
102. Czczeko LEA, Ribas CAPM, Czczeko NG, Skare TL, Yamakawa CK, et al. ARE STEM CELL MARKER EXPRESSION AND CD133 ANALYSIS RELEVANT TO DIFFERENTIATE COLORECTAL CANCER? *Arq Bras Cir Dig*. 2021
103. Yeo MK, Lee YM, Seong IO, Choi SY, Suh KS, et al. Up-regulation of Cytoplasmic CD24 Expression Is Associated with Malignant Transformation but Favorable Prognosis of Colorectal Adenocarcinoma. *Anticancer Res*. 2016